Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
The report of the phase II randomized trial of MEK inhibitor selumetinib for KRAS mutation-positive NSCLC was just published in Lancet Oncology. Here's my discussion of some of the highlights of this work and what this means.
[powerpress]
I'm hoping we'll have more information to update everyone on the developments in the story of MEK inhibitors for KRAS mutation-positive NSCLC, and perhaps also a broader population of patients with NSCLC, in the next year or two.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
